Compare VERU & COSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VERU | COSM |
|---|---|---|
| Founded | 1971 | 2009 |
| Country | United States | Greece |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Pharmaceuticals |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.9M | 33.8M |
| IPO Year | 1996 | 2009 |
| Metric | VERU | COSM |
|---|---|---|
| Price | $2.30 | $0.33 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $25.67 | N/A |
| AVG Volume (30 Days) | 192.8K | ★ 3.6M |
| Earning Date | 08-10-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 46.15 |
| EPS | ★ N/A | N/A |
| Revenue | $16,296,958.00 | ★ $65,271,815.00 |
| Revenue This Year | N/A | $23.79 |
| Revenue Next Year | N/A | $58.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 19.93 |
| 52 Week Low | $2.05 | $0.16 |
| 52 Week High | $7.33 | $1.14 |
| Indicator | VERU | COSM |
|---|---|---|
| Relative Strength Index (RSI) | 43.23 | 50.03 |
| Support Level | $2.12 | $0.27 |
| Resistance Level | $2.78 | $0.35 |
| Average True Range (ATR) | 0.16 | 0.04 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 28.13 | 27.61 |
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
Cosmos Health Inc is a diversified, vertically integrated healthcare group, owner of proprietary pharmaceutical and nutraceutical brands, generics, manufacturer and distributor of healthcare products, engaged in research & development of medicines and repurposing drugs as well as operator of a telehealth platform. The company has developed its own proprietary branded nutraceutical products, named 'Sky Premium Life' and 'Mediterranation'. Its product portfolio includes generics and over-the-counter pharmaceutical products, medicines, as well as nutraceuticals and biocides. The company's Reportable segments are Wholesale, Pharma manufacturing, and Nutraceutical and pharmaceuticals, with the majority of revenue generated from the Wholesale segment.